LON:EVG

Evgen Pharma (EVG) Share Price, News & Analysis

Evgen Pharma logo

About Evgen Pharma Stock (LON:EVG)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
227,410 shs
Average Volume
1.73 million shs
Market Capitalization
£3.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Receive EVG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evgen Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EVG Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
TheraCryf Reports Positive SFX-01 Study Results
Passing of Dr Sue Foden, Chair
See More Headlines

EVG Stock Analysis - Frequently Asked Questions

Evgen Pharma plc (LON:EVG) released its quarterly earnings results on Monday, June, 15th. The company reported GBX (2.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of GBX (2.10).

Based on aggregate information from My MarketBeat watchlists, some other companies that Evgen Pharma investors own include Tesco (TSCO), PIMCO Dynamic Income Fund (PDI), UBS ETRACS Alerian MLP Index ETN (AMU), Atalaya Mining (AYM), Andalas Energy and Power (ADL), Aethlon Medical (AEMD) and Abrdn Income Credit Strategies Fund (ACP).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Finance
Industry
Financial Services
Sub-Industry
Diversified Financial Services
Current Symbol
LON:EVG
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£3.35 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-60.57%
Return on Assets
-45.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.39
Quick Ratio
23.15

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
1.71
Book Value
GBX 1 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
427,350,000
Free Float
N/A
Market Cap
£3.42 million
Optionable
Not Optionable
Beta
1.44
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (LON:EVG) was last updated on 4/25/2024 by MarketBeat.com Staff.
From Our Partners